Cargando…

Association of glial and neuronal degeneration markers with Alzheimer’s disease cerebrospinal fluid profile and cognitive functions

BACKGROUND: Neuroinflammation has gained increasing attention as a potential contributing factor in the onset and progression of Alzheimer’s disease (AD). The objective of this study was to examine the association of selected cerebrospinal fluid (CSF) inflammatory and neuronal degeneration markers w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Teitsdottir, Unnur D., Jonsdottir, Maria K., Lund, Sigrun H., Darreh-Shori, Taher, Snaedal, Jon, Petersen, Petur H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7404927/ https://www.ncbi.nlm.nih.gov/pubmed/32753068 http://dx.doi.org/10.1186/s13195-020-00657-8

Ejemplares similares

Phenotypic Displays of Cholinergic Enzymes Associate With Markers of Inflammation, Neurofibrillary Tangles, and Neurodegeneration in Pre- and Early Symptomatic Dementia Subjects
por: Teitsdottir, Unnur D., et al.
Publicado: (2022)

Cerebrospinal Fluid C18 Ceramide Associates with Markers of Alzheimer’s Disease and Inflammation at the Pre- and Early Stages of Dementia
por: Teitsdottir, Unnur D., et al.
Publicado: (2021)

Obesity modulates the association between sleep apnea treatment and CHI3L1 levels but not CHIT1 activity in moderate to severe OSA: an observational study
por: Teitsdottir, Unnur Dilja, et al.
Publicado: (2018)

Biomarkers in Alzheimer's Disease and Lewy Body Disorders with Dementia
por: Leyhe, Thomas, et al.
Publicado: (2013)

Fibrillar β-amyloid 1-42 alters cytokine secretion, cholinergic signalling and neuronal differentiation
por: Malmsten, Linn, et al.
Publicado: (2014)

Visual hallucinations in Alzheimer's disease do not seem to be associated with chronic hypoperfusion of to visual processing areas V2 and V3 but may be associated with reduced cholinergic input to these areas
por: Sinclair, Lindsey Isla, et al.
Publicado: (2019)

Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis
por: Martínez, M Alba Mañé, et al.
Publicado: (2015)

CSF Cholinergic Index, a New Biomeasure of Treatment Effect in Patients With Alzheimer’s Disease
por: Karami, Azadeh, et al.
Publicado: (2019)

Amyloid-β peptides act as allosteric modulators of cholinergic signalling through formation of soluble BAβACs
por: Kumar, Rajnish, et al.
Publicado: (2016)

Novel ligands of Choline Acetyltransferase designed by in silico molecular docking, hologram QSAR and lead optimization
por: Kumar, Rajnish, et al.
Publicado: (2016)

Homomeric and Heteromeric Aβ Species Exist in Human Brain and CSF Regardless of Alzheimer’s Disease Status and Risk Genotype
por: Lana, Erica, et al.
Publicado: (2019)

Discovery of novel choline acetyltransferase inhibitors using structure-based virtual screening
por: Kumar, Rajnish, et al.
Publicado: (2017)

CSF and Plasma Cholinergic Markers in Patients With Cognitive Impairment
por: Karami, Azadeh, et al.
Publicado: (2021)

Increased Endogenous GDNF in Mice Protects Against Age-Related Decline in Neuronal Cholinergic Markers
por: Mitra, Sumonto, et al.
Publicado: (2021)

Increased Cerebrospinal Fluid S100B and NSE Reflect Neuronal and Glial Damage in Parkinson’s Disease
por: Papuć, Ewa, et al.
Publicado: (2020)

Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease
por: Irwin, David J., et al.
Publicado: (2013)

Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration
por: Mattsson-Carlgren, Niklas, et al.
Publicado: (2022)

Allosteric Binding Sites of Aβ Peptides on the Acetylcholine Synthesizing Enzyme ChAT as Deduced by In Silico Molecular Modeling
por: Baidya, Anurag TK, et al.
Publicado: (2022)

Biomarkers of neurodegeneration and glial activation validated in Alzheimer’s disease assessed in longitudinal cerebrospinal fluid samples of Parkinson’s disease
por: Bartl, Michael, et al.
Publicado: (2021)

Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum
por: Benedet, Andréa L., et al.
Publicado: (2021)

Association of Clusterin Levels in Cerebrospinal Fluid with Synaptic Degeneration Across the Alzheimer’s Disease Continuum
por: Wang, Jun, et al.
Publicado: (2020)

Soluble Aβ42 Acts as Allosteric Activator of the Core Cholinergic Enzyme Choline Acetyltransferase
por: Kumar, Amit, et al.
Publicado: (2018)

Feasibility and therapeutical potential of local intracerebral encapsulated cell biodelivery of BDNF to App(NL−G−F) knock-in Alzheimer mice
por: Tambaro, Simone, et al.
Publicado: (2023)

SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease
por: Brinkmalm, Ann, et al.
Publicado: (2014)

Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer’s disease
por: Kadir, Ahmadul, et al.
Publicado: (2011)

Glial fibrillary acidic protein in cerebrospinal fluid of patients with spinal muscular atrophy
por: Freigang, Maren, et al.
Publicado: (2022)

Increased Active OMI/HTRA2 Serine Protease Displays a Positive Correlation with Cholinergic Alterations in the Alzheimer’s Disease Brain
por: Darreh-Shori, Taher, et al.
Publicado: (2018)

Effect of physical exercise on markers of neuronal dysfunction in cerebrospinal fluid in patients with Alzheimer's disease
por: Jensen, Camilla Steen, et al.
Publicado: (2017)

Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease
por: Visser, Pieter Jelle, et al.
Publicado: (2022)

Fast Alpha Activity in EEG of Patients With Alzheimer’s Disease Is Paralleled by Changes in Cognition and Cholinergic Markers During Encapsulated Cell Biodelivery of Nerve Growth Factor
por: Eyjolfsdottir, Helga, et al.
Publicado: (2022)

Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer’s disease
por: Sutphen, Courtney L., et al.
Publicado: (2018)

Metabolite Profiling of Alzheimer's Disease Cerebrospinal Fluid
por: Czech, Christian, et al.
Publicado: (2012)

Analysis of the Cerebrospinal Fluid Proteome in Alzheimer's Disease
por: Khoonsari, Payam Emami, et al.
Publicado: (2016)

Alzheimer disease pathology and the cerebrospinal fluid proteome
por: Dayon, Loïc, et al.
Publicado: (2018)

Cerebrospinal fluid in Alzheimer's: A precious tool
por: Parnetti, Lucilla, et al.
Publicado: (2016)

Tau oligomers in cerebrospinal fluid in Alzheimer's disease
por: Sengupta, Urmi, et al.
Publicado: (2017)

Oxysterols and Oxysterol Sulfates in Alzheimer’s Disease Brain and Cerebrospinal Fluid
por: Dias, Irundika H.K., et al.
Publicado: (2022)

Neuronal pentraxin receptor-1 is a new cerebrospinal fluid biomarker of Alzheimer’s disease progression
por: Begcevic, Ilijana, et al.
Publicado: (2018)

Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease
por: Visser, Pieter Jelle, et al.
Publicado: (2022)

Glial degeneration with oxidative damage drives neuronal demise in MPSII disease
por: Zalfa, Cristina, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_vi4asasb9io3tk6n461385jhmt